Zacks Research Issues Pessimistic Outlook for UTHR Earnings

United Therapeutics Co. (NASDAQ:UTHR) – Zacks Research decreased their Q1 2025 earnings per share (EPS) estimates for shares of United Therapeutics in a research report issued to clients and investors on Monday, March 17th. Zacks Research analyst R. Department now anticipates that the biotechnology company will earn $6.36 per share for the quarter, down from their prior forecast of $6.93. The consensus estimate for United Therapeutics’ current full-year earnings is $24.48 per share. Zacks Research also issued estimates for United Therapeutics’ Q2 2025 earnings at $6.71 EPS, Q3 2025 earnings at $6.95 EPS, Q4 2025 earnings at $6.68 EPS, FY2025 earnings at $26.69 EPS, Q1 2026 earnings at $6.48 EPS, Q2 2026 earnings at $6.76 EPS, Q3 2026 earnings at $7.12 EPS, Q4 2026 earnings at $7.36 EPS, FY2026 earnings at $27.73 EPS and FY2027 earnings at $28.24 EPS.

Other equities research analysts also recently issued reports about the stock. UBS Group boosted their target price on shares of United Therapeutics from $415.00 to $475.00 and gave the stock a “buy” rating in a research report on Wednesday, January 8th. StockNews.com cut shares of United Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Thursday, February 27th. Finally, HC Wainwright reiterated a “buy” rating and issued a $425.00 target price on shares of United Therapeutics in a research note on Thursday, February 27th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have issued a buy rating to the company’s stock. Based on data from MarketBeat, United Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $388.25.

United Therapeutics Stock Down 1.6 %

UTHR stock opened at $313.60 on Wednesday. The company’s fifty day simple moving average is $346.14 and its 200 day simple moving average is $357.34. United Therapeutics has a 12-month low of $221.53 and a 12-month high of $417.82. The firm has a market cap of $14.08 billion, a price-to-earnings ratio of 13.77, a PEG ratio of 0.97 and a beta of 0.64.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings data on Wednesday, February 26th. The biotechnology company reported $6.19 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.10 by $0.09. The business had revenue of $735.90 million for the quarter, compared to analysts’ expectations of $734.74 million. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. During the same period last year, the firm posted $4.36 earnings per share.

Insider Transactions at United Therapeutics

In other United Therapeutics news, COO Michael Benkowitz sold 10,000 shares of the company’s stock in a transaction dated Monday, February 24th. The shares were sold at an average price of $360.76, for a total value of $3,607,600.00. Following the transaction, the chief operating officer now owns 2,577 shares of the company’s stock, valued at $929,678.52. This represents a 79.51 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Nilda Mesa sold 255 shares of the company’s stock in a transaction that occurred on Monday, December 30th. The stock was sold at an average price of $355.77, for a total transaction of $90,721.35. Following the sale, the director now owns 5,528 shares in the company, valued at $1,966,696.56. The trade was a 4.41 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 90,255 shares of company stock valued at $32,614,521 in the last 90 days. 11.90% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On United Therapeutics

Several hedge funds have recently added to or reduced their stakes in UTHR. Wealthfront Advisers LLC increased its stake in United Therapeutics by 2,090,573.5% in the fourth quarter. Wealthfront Advisers LLC now owns 18,314,300 shares of the biotechnology company’s stock valued at $6,462,018,000 after purchasing an additional 18,313,424 shares during the last quarter. Norges Bank acquired a new stake in shares of United Therapeutics during the fourth quarter worth $151,764,000. FMR LLC lifted its holdings in shares of United Therapeutics by 36.5% during the fourth quarter. FMR LLC now owns 1,471,405 shares of the biotechnology company’s stock worth $519,170,000 after purchasing an additional 393,777 shares during the period. World Investment Advisors LLC acquired a new stake in shares of United Therapeutics during the third quarter worth $139,206,000. Finally, Thrivent Financial for Lutherans lifted its holdings in shares of United Therapeutics by 1,325.5% during the fourth quarter. Thrivent Financial for Lutherans now owns 204,299 shares of the biotechnology company’s stock worth $72,085,000 after purchasing an additional 189,967 shares during the period. 94.08% of the stock is currently owned by hedge funds and other institutional investors.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.